We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

25 hedge funds and large institutions have $3.37M invested in SAB Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

13% more capital invested

Capital invested by funds: $2.99M → $3.37M (+$375K)

3.23% less ownership

Funds ownership: 23.94% → 20.71% (-3.2%)

4% less funds holding

Funds holding: 26 → 25 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
25
Holders Change
-1
Holders Change %
-3.85%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$28.3K
2
Creative Planning
Creative Planning
Kansas
+$19.6K
3
UBS Group
UBS Group
Switzerland
+$17.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$8.04K
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.66K

Top Sellers

Rank Fund Capital Flow
1
HWM
HB Wealth Management
Georgia
-$358K
2
SOS
Silver Oak Securities
Tennessee
-$29.9K
3
BlackRock
BlackRock
New York
-$25.3K
4
XT
XTX Topco
Cayman Islands
-$22.3K
5
Millennium Management
Millennium Management
New York
-$22.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$1.61M – – –
SC
2
Sessa Capital
New York
$805K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$494K +$8.04K +4,861 +2%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$148K +$144 +87 +0.1%
Pathstone Holdings
5
Pathstone Holdings
New Jersey
$88.9K – – –
Kovitz Investment Group Partners
6
Kovitz Investment Group Partners
Illinois
$33.7K – – –
FPB
7
First PREMIER Bank
South Dakota
$33K – – –
Citadel Advisors
8
Citadel Advisors
Florida
$29.9K +$28.3K +17,095 New
KAS
9
Kestra Advisory Services
Texas
$20.9K – – –
Creative Planning
10
Creative Planning
Kansas
$20.8K +$19.6K +11,852 New
Northern Trust
11
Northern Trust
Illinois
$20K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$19.4K +$1.66K +1,000 +10%
UBS Group
13
UBS Group
Switzerland
$18.7K +$17.5K +10,580 +13,564%
BlackRock
14
BlackRock
New York
$12.3K -$25.3K -15,295 -69%
Osaic Holdings
15
Osaic Holdings
Arizona
$8.64K -$17 -10 -0.2%
S
16
Sachetta
Massachusetts
$7.2K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$1.27K +$1.15K +692 +2,035%
MCM
18
MAI Capital Management
Ohio
$381 – – –
GI
19
GS Investments
Minnesota
$351 – – –
Morgan Stanley
20
Morgan Stanley
New York
$295 -$465 -281 -63%
JP Morgan Chase
21
JP Morgan Chase
New York
$152 -$26 -16 -16%
Bank of America
22
Bank of America
North Carolina
$128 +$10 +6 +9%
HI
23
Harbour Investments
Wisconsin
$88 – – –
SS
24
SBI Securities
Japan
$88 – – –
Raymond James Financial
25
Raymond James Financial
Florida
$79 +$74 +45 New
1
2

SABS Hedge Fund Activity: Q2 2025 in Review

25 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2025, worth a combined $3.37M — up 13% from $2.99M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SABS and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $28.3K. The largest seller was HB Wealth Management, exiting entirely with an estimated $358K sold.

  • 25 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2025, down from 26 in Q1 2025.
  • Funds reported $3.37M of SAB Biotherapeutics stock for Q2 2025, up 13% quarter-over-quarter.
  • 3 funds opened new SAB Biotherapeutics positions in Q2 2025 and 4 closed out, a net change of -1 holder.
  • The largest SAB Biotherapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $28.3K added.
  • The largest SAB Biotherapeutics seller in Q2 2025 was HB Wealth Management, an estimated $358K sold.

Based on aggregated 13F filings for Q2 2025.